2013
Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC).
Raftopoulos H, Aisner J, Kumar K, Goel S, Dittrich C, Jain M, Gopalakrishna P, Salazar P, Jones B, Petrylak D. Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: e19145-e19145. DOI: 10.1200/jco.2013.31.15_suppl.e19145.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerDisease control rateProgression-free survivalDuration of responseChemo-naïve patientsAdverse eventsOverall survivalEribulin mesylateDay 1Platinum-based doublet chemotherapyOverall objective response rateCarboplatin AUC 6Combination of eribulinCommon adverse eventsObjective response rateUnexpected safety findingsDose-escalation studyCell lung cancerLung cancer cell linesAUC 6Doublet chemotherapyFebrile neutropeniaMeasurable diseaseCancer cell lines
2009
Strategies to Circumvent Resistance to Apoptosis in Prostate Cancer Cells by Targeted Necrosis
Dinnen R, Petrylak D, Fine R. Strategies to Circumvent Resistance to Apoptosis in Prostate Cancer Cells by Targeted Necrosis. 2009, 327-346. DOI: 10.1007/978-1-4020-9597-9_14.Peer-Reviewed Original ResearchProstate cancer cellsCancer cellsCircumvent resistanceCancer linesHuman prostate cancer cellsProstate cancer cell linesMutant p53Prostate cancer linesNormal cellsCancer cell linesMechanism of cytotoxicityChemotherapy resistanceNecrosisDrug resistanceReactive oxygen speciesHigh levelsSelective killingApoptosisCell linesIntracellular generationNecrotic pathwaysP53Cell deathDeath pathwaysOxygen species
2007
Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy
Molife R, Cartwright T, Loesch D, Garbo L, Sonpavde G, Calvo E, Das A, Wanders J, Petrylak D, de Bono J. Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy. Journal Of Clinical Oncology 2007, 25: 15513-15513. DOI: 10.1200/jco.2007.25.18_suppl.15513.Peer-Reviewed Original ResearchHormone-refractory prostate cancerRefractory prostate cancerPSA responsePrior chemotherapyProstate cancerNon-small cell lung cancerSmall cell lung cancerPhase II multicenterRefractory breast cancerSerious adverse eventsSingle-agent activityCell lung cancerProstate cancer cell linesBolus IV infusionTwo-stage studyConcomitant steroidsCancer cell linesChest painFebrile neutropeniaStudy drugAcceptable toxicityMetastatic diseasePrior regimenRenal failureAdverse events